Form 8-K

8-K — Vivos Therapeutics, Inc.

Accession: 0001493152-26-028912

Filed: 2026-06-16

Period: 2026-06-16

CIK: 0001716166

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001716166

2026-06-16

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): June 16,

2026 (June 11, 2026)

Vivos

Therapeutics, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-39796

81-3224056

(State

or other jurisdiction

(Commission

(I.R.S.

Employer

incorporation)

File

Number)

Identification

No.)

7921

Southpark Plaza, Suite 210

Littleton,

Colorado 80120

(Address

of principal executive offices) (Zip Code)

(866)

908-4867

(Registrant’s

telephone number, including area code)

N/A

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, par value $0.0001 per share

VVOS

The

NASDAQ Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933

(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

8.01. Other Events.

June 11, 2026, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its intention to file a registration

statement with the U.S. Securities and Exchange Commission (the “SEC”) for a proposed rights offering, pursuant to which

the Company would distribute, as a dividend, transferable subscription rights to its shareholders. Subject to and following the SEC declaring

the registration statement effective, the Company intends to distribute the rights as a dividend to shareholders as of a proposed record

date to be set as the 30th day following the date on which the registration statement is declared effective by the SEC.

described in the press release, each right is expected to entitle the holder to purchase one share of the Company’s common stock

at an exercise price equal to the greater of $1.25 per share or 20% above the market price on the day before the record date, with the

final exercise price to be set forth in the prospectus. The rights are intended to be listed for trading on a securities exchange, subject

to satisfaction of applicable listing and regulatory requirements, and are expected to be exercisable for a period of nine months. Upon

exercise of a right, the holder is expected to receive a subsequent nine-month trading right with an expected exercise price equal to

the greater of $1.75 per share or 40% above the market price on the day before the record date. The foregoing terms are preliminary and

indicative only, and the final terms of the proposed rights offering, if commenced, will be set forth in the prospectus included in the

registration statement.

The

proposed rights offering remains subject to a number of conditions, any of which could delay, alter, or prevent its completion, including,

without limitation, the SEC declaring the registration statement effective; compliance with the applicable rules of any applicable securities

exchange, including any shareholder-approval requirements that may apply; the availability of a sufficient number of authorized but unissued

shares of common stock, which may require an amendment to the Company’s certificate of incorporation and a shareholder vote; required

approvals by the Company’s Board of Directors; and prevailing market conditions. There can be no assurance that any or all of these

conditions will be satisfied, and the Company reserves the right to modify, postpone, or terminate the proposed rights offering at any

time prior to completion.

copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

This

Current Report on Form 8-K, including the press release filed as Exhibit 99.1, does not constitute an offer to sell or the solicitation

of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer,

solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Any offering of securities will be made only by means of a prospectus meeting the requirements of Section 10 of the Securities Act of

1933, as amended.

Cautionary

Note Regarding Forward-Looking Statements

This

Current Report on Form 8-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act

of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the Company’s

intention to file a registration statement for the proposed rights offering; the anticipated timing of such filing and of effectiveness;

the proposed distribution of subscription rights as a dividend and the proposed record date therefor; the expected terms of the rights,

including the expected exercise price, the contemplated transferability of the rights, the exercise period, and any subsequent rights

issuable upon exercise; and the Company’s ability to commence, structure and complete the proposed offering on the contemplated

terms or at all. These statements are based on current expectations and assumptions and are subject to significant known and unknown

risks and uncertainties, many of which are beyond the Company’s control, including whether and when the SEC will declare the registration

statement effective; the risk that the proposed offering is delayed, modified, postponed or abandoned; the Company’s ability to

satisfy the conditions to the offering, including listing and any applicable shareholder-approval requirements; the availability of sufficient

authorized but unissued shares of common stock; the uncertain tax treatment to shareholders of the receipt, ownership, sale or exercise

of transferable rights received as a dividend; the Company’s ability to access capital on acceptable terms or at all; and general

economic and market conditions. Actual results may differ materially and adversely from those expressed or implied by such forward-looking

statements. Additional information regarding factors that may cause actual results to differ materially is included in the Company’s

filings with the SEC, which may be obtained free of charge at https://vivos.com/investors/sec-filings/. Except to the extent required

by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

99.1

Press Release of Vivos Therapeutics, Inc., dated June 11, 2026.

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

VIVOS

THERAPEUTICS, INC.

Date:

June 16, 2026

By:

/s/

R. Kirk Huntsman

Name:

R. Kirk Huntsman

Title:

Chief Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Vivos

Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

LITTLETON,

Colo., June 11, 2026 — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a

leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic

health conditions, including mild-to-severe obstructive sleep apnea (“OSA”) , today announced that it intends to file a registration

statement with the U.S. Securities and Exchange Commission (the “SEC”) for a proposed rights offering pursuant to which the

Company would distribute, as a dividend, transferable subscription rights to its shareholders.

The

Company currently expects to file a registration statement in connection with the proposed rights offering. Subject to and following

the SEC declaring the registration statement effective, the Company intends to distribute the rights as a dividend to shareholders as

of a proposed record date to be set as the 30th day following the registration statement being declared effective by the SEC.

The timing of the proposed rights offering is solely dependent upon the SEC declaring the future registration statement effective, and

there can be no assurance as to whether or when effectiveness will occur.

Key

Terms of the Proposed Rights Offering

●

Exercise

price: Each right is expected to entitle the holder to purchase one share of Vivos common stock at an exercise price that is

the greater of $1.25 per share or 20% above the market price on the day before the record date as defined above. The final

exercise price will be set forth in the prospectus.

●

Trading

and transferability: The rights are intended to be listed for trading on a securities exchange, subject to satisfaction

of applicable listing requirements and any regulatory requirements.

●

Term:

The rights will be exercisable for a period of nine (9) months.

●

Subsequent

(“exploding”) right: Upon exercise of a right, the holder is expected to receive a similar nine-month trading

right with an expected exercise price that is the greater of $1.75 per share or 40% above the market on the day before the

record date. The terms of any subsequent right will be described in the prospectus.

The

foregoing terms are preliminary and indicative only. The final terms of the proposed rights offering, if commenced, will be set forth

in the prospectus included in the registration statement. The Company reserves the right to modify any or all of the foregoing terms

at any time.

Conditions

to Completion of the Proposed Rights Offering

The

proposed rights offering remains subject to a number of conditions, any of which could delay, alter, or prevent its completion. These

include, without limitation: (i) the preparation, filing, and the SEC declaring effective a registration statement covering the rights,

the underlying shares of common stock, and the subsequent rights; (ii) compliance with applicable rules of any applicable securities

exchange, including any shareholder-approval requirements that may apply and the listing of the new securities; (iii) the availability

of a sufficient number of authorized but unissued shares of common stock, which may require an amendment to the Company’s certificate

of incorporation and a shareholder vote; (iv) all required approvals and authorizations by the Company’s Board of Directors; (v)

the absence of any conflict with the Company’s organizational documents or existing contractual obligations, including its outstanding

financing arrangements and warrants; (vi) registration or qualification under applicable state securities or ‘blue sky’ laws,

or the availability of an exemption therefrom; and (vii) prevailing market conditions. There can be no assurance that any or all of these

conditions will be satisfied, and the Company reserves the right to modify, postpone, or terminate the proposed rights offering at any

time prior to completion. The timing of the proposed rights offering is solely dependent upon the SEC declaring the planned future registration

statement effective.

Management

Commentary

“We

are pleased to move forward with our plans to prepare a registration statement for a proposed rights offering, which, if completed, is

intended to provide the Company with additional capital to support its operations and general corporate purposes,” said R. Kirk

Huntsman, Chief Executive Officer of Vivos Therapeutics. The Company can give no assurance that the proposed rights offering will

be commenced or completed, and any offering will be made only by means of a prospectus.

The

Company intends to provide additional details regarding the record date, distribution ratio, and other terms of the proposed rights offering

if and when the registration statement is filed and subsequently declared effective by the SEC.

This

press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale

of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or

qualification under the securities laws of any such state or jurisdiction. Any offering of securities will be made only by means of a

prospectus meeting the requirements of the Securities Act of 1933, as amended. No money or other consideration is being solicited, and

if sent in response, will not be accepted.

About

Vivos Therapeutics, Inc.

Vivos

Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative

diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities

such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration

(FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’

groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating

severe OSA in adults and the first to receive clearance for treating moderate-to-severe OSA in children.

OSA

affects over 1 billion people worldwide, yet 80% or more remain undiagnosed and unaware of their condition. This chronic disorder is

not just a sleep issue—it is closely linked to many serious chronic health conditions. While the medical community has made strides

in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments

like CPAP are often mechanistic and fail to address the root causes of OSA.

Founded

in 2016 and based in Littleton, Colorado, Vivos is working to change this. Through innovative technology, education, and acquisitions

of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs

of OSA patients more thoroughly.

Vivos

calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective

solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.

For

more information, visit www.vivos.com.

Forward-Looking

Statements

This

press release and statements of the Company’s management contains “forward-looking statements” (as defined in Section

27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future

events. Words such as “may”, “should”, “expects”, “projects,” “intends”,

“plans”, “believes”, “anticipates”, “hopes”, “estimates”, “aim,”

“goal” and derivations of such words and similar expressions about the future are intended to identify forward-looking statements.

These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently

subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Forward-looking statements include,

without limitation, statements regarding: the Company’s intention to file a registration statement with the SEC for the proposed

rights offering; the anticipated timing of such filing and of effectiveness; the proposed distribution of subscription rights as a dividend

to shareholders and the proposed record date therefor; the expected terms of the rights, including the expected subscription price, the

subscription ratio, the duration of the exercise period, the contemplated transferability of the rights, and any subsequent rights issuable

upon exercise; the anticipated manner and purpose of the offering; and the Company’s ability to commence, structure and complete

the proposed offering on the contemplated terms or at all. Actual results may differ materially and adversely from those expressed or

implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited

to: (i) whether and when the SEC will declare the registration statement effective; the risk that the proposed offering is delayed, modified,

postponed or abandoned prior to completion; (ii) the Company’s ability to satisfy the conditions to the offering, including the

listing of the new securities on, and compliance with the applicable rules of, The Nasdaq Stock Market and/or any applicable securities

exchange, and any shareholder-approval requirements that may apply; (iii) the availability of a sufficient number of authorized but unissued

shares of common stock, which may require an amendment to the Company’s certificate of incorporation and a shareholder vote; (iv)

final approval and authorization by the Company’s Board of Directors; (v) the absence of any conflict with the Company’s

organizational documents or existing contractual obligations, including its outstanding financing arrangements and warrants; (vi) the

trading price and trading volume of the Company’s common stock and of the rights, including in relation to the exercise price;

(vii) the uncertain tax treatment to shareholders of the receipt, ownership, sale or exercise of transferable rights received as a dividend;

(viii) the Company’s ability to access capital on acceptable terms or at all; (ix) the level of participation by shareholders in

the offering and the amount of proceeds, if any, ultimately realized; (x) general economic and market conditions and (xi) other risk

factors described in Vivos’ filings with the SEC. Vivos’ filings can be obtained free of charge at https://vivos.com/investors/sec-filings/.

Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions

to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change

in events, conditions, or circumstances on which any statement is based.

Investor

Relations Contact

Vivos

Therapeutics, Inc.

Jennifer Hauser

investors@vivoslife.com

###

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Jun. 16, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 16, 2026

Entity File Number

001-39796

Entity Registrant Name

Vivos

Therapeutics, Inc.

Entity Central Index Key

0001716166

Entity Tax Identification Number

81-3224056

Entity Incorporation, State or Country Code

Entity Address, Address Line One

7921

Southpark Plaza

Entity Address, Address Line Two

Suite 210

Entity Address, City or Town

Littleton

Entity Address, State or Province

Entity Address, Postal Zip Code

80120

City Area Code

(866)

Local Phone Number

908-4867

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.0001 per share

Trading Symbol

VVOS

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration